Cantargia AB
STO:CANTA
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.79
5
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Cantargia AB
Intangible Assets
Cantargia AB
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Cantargia AB
STO:CANTA
|
Intangible Assets
kr4m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Biogaia AB
STO:BIOG B
|
Intangible Assets
kr46.2m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
||
Bonesupport Holding AB
STO:BONEX
|
Intangible Assets
kr14.2m
|
CAGR 3-Years
19%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
||
Vitrolife AB
STO:VITR
|
Intangible Assets
kr4.3B
|
CAGR 3-Years
152%
|
CAGR 5-Years
63%
|
CAGR 10-Years
74%
|
||
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Intangible Assets
kr48.1B
|
CAGR 3-Years
15%
|
CAGR 5-Years
15%
|
CAGR 10-Years
34%
|
||
BioArctic AB
STO:BIOA B
|
Intangible Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Cantargia AB
Glance View
Cantargia AB is a holding company, which engages in the development of antibody-based cancer treatment. The company is headquartered in Lund, Skane. The company went IPO on 2015-03-17. The firm is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.
See Also
What is Cantargia AB's Intangible Assets?
Intangible Assets
4m
SEK
Based on the financial report for Sep 30, 2024, Cantargia AB's Intangible Assets amounts to 4m SEK.
What is Cantargia AB's Intangible Assets growth rate?
Intangible Assets CAGR 3Y
-16%
Over the last year, the Intangible Assets growth was -18%. The average annual Intangible Assets growth rates for Cantargia AB have been -16% over the past three years .